As for the later-mentioned direct KRAS G12C inhibitor, combinations of MRTX 849 with agents including the HER family inhibitor afatinib, the CDK4/6 inhibitor palbociclib, the SHP2 inhibitor RMC-4550, and different mTOR pathway inhibitors demonstrated enhanced response and marked tumor regression in several cell-line panels and tumor models, including MRTX 849-refractory models as well [115]. This evidence concerns the gene CDK4 and neoplasm.